Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data
Autor: | Kayode Ogungbenro, Hitesh Mistry, Leon Aarons, Thierry Wendling |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Oncology Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Toxicology Deoxycytidine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Pancreatic cancer Tumour size time-series Metastatic pancreatic cancer Humans Medicine Pharmacology (medical) Hierarchical modelling Survival analysis Proportional Hazards Models Retrospective Studies Pharmacology business.industry Proportional hazards model Retrospective cohort study Models Theoretical Prognosis medicine.disease Gemcitabine Tumor Burden Pancreatic Neoplasms 030104 developmental biology Clinical Trials Phase III as Topic chemistry Tumour size 030220 oncology & carcinogenesis Original Article business medicine.drug |
Zdroj: | Cancer Chemotherapy and Pharmacology |
ISSN: | 1432-0843 0344-5704 |
DOI: | 10.1007/s00280-016-2994-x |
Popis: | Purpose Measures derived from longitudinal tumour size data have been increasingly utilised to predict survival of patients with solid tumours. The aim of this study was to examine the prognostic value of such measures for patients with metastatic pancreatic cancer undergoing gemcitabine therapy. Methods The control data from two Phase III studies were retrospectively used to develop (271 patients) and validate (398 patients) survival models. Firstly, 31 baseline variables were screened from the training set using penalised Cox regression. Secondly, tumour shrinkage metrics were interpolated for each patient by hierarchical modelling of the tumour size time-series. Subsequently, survival models were built by applying two approaches: the first aimed at incorporating model-derived tumour size metrics in a parametric model, and the second simply aimed at identifying empirical factors using Cox regression. Finally, the performance of the models in predicting patient survival was evaluated on the validation set. Results Depending on the modelling approach applied, albumin, body surface area, neutrophil, baseline tumour size and tumour shrinkage measures were identified as potential prognostic factors. The distributional assumption on survival times appeared to affect the identification of risk factors but not the ability to describe the training data. The two survival modelling approaches performed similarly in predicting the validation data. Conclusions A parametric model that incorporates model-derived tumour shrinkage metrics in addition to other baseline variables could predict reasonably well survival of patients with metastatic pancreatic cancer. However, the predictive performance was not significantly better than a simple Cox model that incorporates only baseline characteristics. Electronic supplementary material The online version of this article (doi:10.1007/s00280-016-2994-x) contains supplementary material, which is available to authorized users. |
Databáze: | OpenAIRE |
Externí odkaz: |